[Ip-health] Survey: 7 out of 8 persons say US residents should not pay more than other high income countries for NIH funded drugs
claire.cassedy at keionline.org
Thu Aug 29 09:21:56 PDT 2013
Survey: 7 out of 8 persons say US residents should not pay more than other
high income countries for NIH funded drugs
Seven out of eight persons want the NIH to use its rights in federally
funded patents to prevent U.S. consumers from paying more than other high
income countries, according to a survey of 160 randomly selected U.S.
residents. The survey was conducted August 26 to August 28, 2013, and
involved two questions regarding NIH funded drug development.
Respondents were provided with data regarding Survey: 7 out of 8 persons
say US residents should not pay more than other high income countries for
NIH funded drugsthe US National Institutes of Health (NIH) overall budget
as well as the amount budgeted for HIV/AIDS research. The background
information also gave the percentages of US patents that benefited from US
taxpayer funding of research that contained the terms 'cancer' and 'HIV' in
the patent claims (19% and 23% respectively) from 2010 to 2011. The first
Were you previously aware of the extent of US government funding of medical
research, including research that leads to patented inventions?
Results: Yes, 38 percent. No, 62 percent.
On the topic of US drug prices as compared to other high-income countries,
respondents were provided with data regarding a policy the NIH has been
asked to adopt. The policy in question asks the NIH to grant new
non-discriminatory licenses to generic drug manufacturers to use the
patents on NIH funded drug discoveries when drugs are more expensive in the
US than in other high-income countries. It then presents the perspective of
drug companies, who argue that patent owners/drug companies should be free
to charge US residents higher prices, regardless of the financing of the
drug's research and development. The question asked was as follows:
The U.S. National Institutes of Health (NIH), a government agency, has
rights to the patents for dozens of drugs that were developed with federal
funds. Should the NIH require patent holders to charge no more to residents
of the United States than the prices in Canada, Europe and other
high-income countries, for the same drug?
Results: Yes, 71.7 percent. No, 9.6 percent. Not sure 18.7 percent.
Please visit (www.keionline.org/node/1792<http://www.keionline.org/node1792>)
to access as PDF and spreadsheet files the survey questions 1 and 2 as
viewed by respondents, the summary results of the survey, including
respondents' demographic information, and the detailed responses for each
Charts showing the cross tabulations for answers to questions 1 and 2 by
education and gender are also shown in the Appendix, as well as additional
context regarding the current petition asking the NIH to adopt a rule on
the pricing of NIH funded inventions.
NIH current dispute involving patents on ritonavir and other federally
On October 25, 2012, the American Medical Students Association (AMSA),
Knowledge Ecology International (KEI), U.S. Public Interest Research Group
(PIRG) and the Universities Allied for Essential Medicines (UAEM) filed a
petition (http://keionline.org/node/1573) requesting the National
Institutes of Health (NIH) grant Bayh-Dole Act march-in rights for the
patents held by Abbott Laboratories relevant to the manufacture and sale of
ritonavir, a federally funded invention that is much more expensive in the
United States than in Canada, Europe or other high-income countries. The
NIH has yet to grant a hearing on the petition.
The petition focuses on one drug, ritonavir, which is priced 4 to 10 times
higher in the USA than in other high income countries, but asked for a more
general rule that would provide a march-in remedy for any drug when US
prices were higher than other high income countries. The petition cited
data from a survey (attached here) of 14 NIH funded drugs, 13 of which were
priced higher iSurvey: 7 out of 8 persons say US residents should not pay
more than other high income countries for NIH funded drugsn the United
States than in foreign markets, often significantly so.
Notes from the March 18, 2013 NIH Call on the ritonavir March-In Request (
Meredith Wadman, NIH asked to grant open licence on HIV drug (
), Nature News Blog. November 2, 2012.
Please see ((www.keionline.org/node/1792) for the cross tabulations for
answers to questions 1 and 2 by education and gender.
More information about the Ip-health